Measurement Properties of the Hospital Anxiety and Depression Scale Used in Atopic Dermatitis in Adults

Jonathan I. Silverberg; Joel M. Gelfand; David J. Margolis; Mark Boguniewicz; Luz Fonacier; Mitchell H. Grayson; Peck Y. Ong; Zelma C. Chiesa Fuxench; Eric L. Simpson

doi:10.1016/j.jid.2018.11.029

Measurement Properties of the Hospital Anxiety and Depression Scale Used in Atopic Dermatitis in Adults

Jonathan I. Silverberg^*, Joel M. Gelfand, David J. Margolis, Mark Boguniewicz, Luz Fonacier, Mitchell H. Grayson, Peck Y. Ong, Zelma C. Chiesa Fuxench, Eric L. Simpson

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Original language	English (US)
Pages (from-to)	1388-1391
Number of pages	4
Journal	Journal of Investigative Dermatology
Volume	139
Issue number	6
DOIs	https://doi.org/10.1016/j.jid.2018.11.029
State	Published - Jun 2019

ASJC Scopus subject areas

Biochemistry
Molecular Biology
Dermatology
Cell Biology

Access to Document

10.1016/j.jid.2018.11.029

Cite this

@article{8fda562f8f6b4adda55d66ead0c14237,

title = "Measurement Properties of the Hospital Anxiety and Depression Scale Used in Atopic Dermatitis in Adults",

author = "Silverberg, {Jonathan I.} and Gelfand, {Joel M.} and Margolis, {David J.} and Mark Boguniewicz and Luz Fonacier and Grayson, {Mitchell H.} and Ong, {Peck Y.} and {Chiesa Fuxench}, {Zelma C.} and Simpson, {Eric L.}",

note = "Funding Information: The Atopic Dermatitis in America Study is an independent research project of the Asthma and Allergy Foundation of America, in partnership with the National Eczema Association and sponsored by Sanofi Genzyme and Regeneron . Funding Information: The Atopic Dermatitis in America Study is an independent research project of the Asthma and Allergy Foundation of America, in partnership with the National Eczema Association and sponsored by Sanofi Genzyme and Regeneron. JIS had full access to all the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis. Study concept and design: JIS. Acquisition of data: JIS, JMG, DJM, LF, MB, MHG, PYO, and ZCCF. Analysis and interpretation of data: JIS, JMG, DJM, LF, MB, MHG, PYO, and ZCCF. Drafting of the manuscript: JIS. Critical revision of the manuscript for important intellectual content: JIS, JMG, DJM, LF, MB, MHG, PYO, and ZCCF. Statistical analysis: JIS. Administrative technical or material support: None. Study supervision: Asthma and Allergy Foundation of America. Funding Information: JIS served as a consultant and/or advisory board member for Abbvie, AnaptysBio, Asana, Arena, Boehringer-Ingelheim, Dermavant, Eli Lilly, Galderma, GlaxoSmithKline, Glenmark, Kiniksa, Leo, Menlo, Novartis, Pfizer, Regeneron-Sanofi, Realm receiving honoraria; speaker for Regeneron-Sanofi; and received research grants from GlaxoSmithKline. JMG served as a consultant for Bristol-Myers Squibb, Boehringer Ingelheim, Janssen Biologics, Novartis Corp, UCB (Data Safety Monitoring Board), Sanofi and Pfizer Inc., and receives grants (to the Trustees of the University of Pennsylvania) from Abbvie, Janssen, Novartis Corp, Sanofi, Celgene, Ortho Dermatologics, and Pfizer Inc. ZCCF has served as a consultant for the National Eczema Association and the Asthma and Allergy Foundation, receiving honoraria, and receives or has received research grants (to the Trustees of the University of Pennsylvania) from Regeneron, Sanofi, Tioga and Vanda and Menlo pharmaceuticals and Realm Therapeutics for work in atopic dermatitis; and has received payment for continuing medical education work related to atopic dermatitis that was supported indirectly by Regeneron and/or Sanofi. DJM is the chair of the data monitoring committee for all Sunovion clinical trials of dupilumab, and has received independent research funding to his institution from the National Institute of Health and Valeant and is a consultant for Pfizer. MB has received research funding from Regeneron and consulted for Regeneron, Sanofi-Genzyme and Eli Lilly. LF has served as consultant and advisory board member for Regeneron, receiving honoraria; received research and educational grants from Genentech, Regeneron, Baxter, and Pfizer. MHG is a board member of Allergy and Asthma Foundation of America (AAFA) and chair for the AAFA Medical Scientific Council, and has served on advisory boards for AstraZeneca, Novartis, and Genentech. ELS is an investigator for Eli Lilly Co., Galderma, Leo Pharmaceutical Co., Merck, Pfizer, Regeneron Pharmaceuticals, Inc., and a consultant with honorarium for AbbVie Inc., Boehringer-Ingelheim, Dermavant, Eli Lilly Co., Incyte, Leo Pharmaceutical Co., Pfizer, Pierre Fabre Dermo Cosmetique, Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme. PYO is a co-investigator of Atopic Dermatitis Research Network and has consulted for Pfizer and Theravance and has received research funding from Regeneron. ",

year = "2019",

month = jun,

doi = "10.1016/j.jid.2018.11.029",

language = "English (US)",

volume = "139",

pages = "1388--1391",

journal = "Journal of Investigative Dermatology",

issn = "0022-202X",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - Measurement Properties of the Hospital Anxiety and Depression Scale Used in Atopic Dermatitis in Adults

AU - Silverberg, Jonathan I.

AU - Gelfand, Joel M.

AU - Margolis, David J.

AU - Boguniewicz, Mark

AU - Fonacier, Luz

AU - Grayson, Mitchell H.

AU - Ong, Peck Y.

AU - Chiesa Fuxench, Zelma C.

AU - Simpson, Eric L.

N1 - Funding Information: The Atopic Dermatitis in America Study is an independent research project of the Asthma and Allergy Foundation of America, in partnership with the National Eczema Association and sponsored by Sanofi Genzyme and Regeneron . Funding Information: The Atopic Dermatitis in America Study is an independent research project of the Asthma and Allergy Foundation of America, in partnership with the National Eczema Association and sponsored by Sanofi Genzyme and Regeneron. JIS had full access to all the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis. Study concept and design: JIS. Acquisition of data: JIS, JMG, DJM, LF, MB, MHG, PYO, and ZCCF. Analysis and interpretation of data: JIS, JMG, DJM, LF, MB, MHG, PYO, and ZCCF. Drafting of the manuscript: JIS. Critical revision of the manuscript for important intellectual content: JIS, JMG, DJM, LF, MB, MHG, PYO, and ZCCF. Statistical analysis: JIS. Administrative technical or material support: None. Study supervision: Asthma and Allergy Foundation of America. Funding Information: JIS served as a consultant and/or advisory board member for Abbvie, AnaptysBio, Asana, Arena, Boehringer-Ingelheim, Dermavant, Eli Lilly, Galderma, GlaxoSmithKline, Glenmark, Kiniksa, Leo, Menlo, Novartis, Pfizer, Regeneron-Sanofi, Realm receiving honoraria; speaker for Regeneron-Sanofi; and received research grants from GlaxoSmithKline. JMG served as a consultant for Bristol-Myers Squibb, Boehringer Ingelheim, Janssen Biologics, Novartis Corp, UCB (Data Safety Monitoring Board), Sanofi and Pfizer Inc., and receives grants (to the Trustees of the University of Pennsylvania) from Abbvie, Janssen, Novartis Corp, Sanofi, Celgene, Ortho Dermatologics, and Pfizer Inc. ZCCF has served as a consultant for the National Eczema Association and the Asthma and Allergy Foundation, receiving honoraria, and receives or has received research grants (to the Trustees of the University of Pennsylvania) from Regeneron, Sanofi, Tioga and Vanda and Menlo pharmaceuticals and Realm Therapeutics for work in atopic dermatitis; and has received payment for continuing medical education work related to atopic dermatitis that was supported indirectly by Regeneron and/or Sanofi. DJM is the chair of the data monitoring committee for all Sunovion clinical trials of dupilumab, and has received independent research funding to his institution from the National Institute of Health and Valeant and is a consultant for Pfizer. MB has received research funding from Regeneron and consulted for Regeneron, Sanofi-Genzyme and Eli Lilly. LF has served as consultant and advisory board member for Regeneron, receiving honoraria; received research and educational grants from Genentech, Regeneron, Baxter, and Pfizer. MHG is a board member of Allergy and Asthma Foundation of America (AAFA) and chair for the AAFA Medical Scientific Council, and has served on advisory boards for AstraZeneca, Novartis, and Genentech. ELS is an investigator for Eli Lilly Co., Galderma, Leo Pharmaceutical Co., Merck, Pfizer, Regeneron Pharmaceuticals, Inc., and a consultant with honorarium for AbbVie Inc., Boehringer-Ingelheim, Dermavant, Eli Lilly Co., Incyte, Leo Pharmaceutical Co., Pfizer, Pierre Fabre Dermo Cosmetique, Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme. PYO is a co-investigator of Atopic Dermatitis Research Network and has consulted for Pfizer and Theravance and has received research funding from Regeneron.

PY - 2019/6

Y1 - 2019/6

UR - http://www.scopus.com/inward/record.url?scp=85062460838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062460838&partnerID=8YFLogxK

U2 - 10.1016/j.jid.2018.11.029

DO - 10.1016/j.jid.2018.11.029

M3 - Article

C2 - 30571970

AN - SCOPUS:85062460838

SN - 0022-202X

VL - 139

SP - 1388

EP - 1391

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

IS - 6

ER -

Measurement Properties of the Hospital Anxiety and Depression Scale Used in Atopic Dermatitis in Adults

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this